VCEL Vericel


Pro users get this 30m faster
SVB Leerink Maintains Outperform on Vericel, Lowers Price Target to $62
5 Aug 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Danielle Antalffy maintains Vericel (NASDAQ:VCEL) with a Outperform and lowers the price target from $67 to $62.
Vericel Q2 EPS $(0.08), Inline, Sales $39.52M Beat $36.67M Estimate
4 Aug 21
Earnings, News
Vericel (NASDAQ:VCEL) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 55.56 percent increase over losses of $(0.18) per share from the same period last year. The
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
4 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)
Earnings Scheduled For August 4, 2021
4 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Understanding Vericel's Unusual Options Activity
3 Aug 21
Vericel (NASDAQ:VCEL) shares experienced unusual options activity on Tuesday. The stock price moved down to $52.56 following the option alert.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
1 Aug 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.